BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™
Europe
Asia

DIVERSITY

PROFILES
Company Profiles

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Research Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
   

AstraZeneca PLC (AZN) and Pfizer Inc. (PFE) Team Up With $100 Million to Create New Venture and New Jobs


11/26/2012 7:47:01 AM

Two pharmaceutical multinationals are partnering with the Quebec government on what they’re calling a new approach to drug development as a public-private partnership. AstraZeneca Plc and Pfizer Inc. said Friday they would team with Quebec to create the Neomed Institute, a new life sciences research facility in Montreal that will host researchers, university officials and employees from the drug makers as well venture capitalists. The three partners are spending $100-million on the venture, with the largest portion of the financing and the land contributed by AstraZeneca. “The cost of discovering new drugs keeps rising and pharmaceutical companies need to adapt,” the institute’s new president, Max Fehlmann, said in a statement. The research centre is a response to the changing R&D business model in the industry, one in which companies are shifting away from its traditional approach of carrying out research and development activities in-house toward more outsourcing. Neomed aims to bridge the gap between early-stage research and later-stage drug development, the companies said.

Read at Financial Post
Read at CBC

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES
 

//-->